EP4301468
FGFR3 HEMLANDI EFNASAMBÖND
Status:
EP einkaleyfi í gildi á ÍslandiEP appl. date:
3.3.2022EP published:
3.9.2025EP application number:
22712686.9
EP translation filed:
26.11.2025Grant published:
15.12.2025EPO information:
European Patent Register
Max expiry date:
2.3.2042Expiry date:
2.3.2027Next due date:
31.3.2027
Title in English:
FGFR3 INHIBITOR COMPOUNDSLanguage of the patent:
English
Timeline
Today
3.3.2022EP application
3.9.2025EP Publication
26.11.2025Translation submitted
15.12.2025Registration published
2.3.2027Expires
Owner
Name:
Eli Lilly and CompanyAddress:
Lilly Corporate Center, Indianapolis, IN 46285, US
Inventor
Name:
ABRAHAM, Adedoyin DavidAddress:
Indianapolis, Indiana 46206-6288, US
Name:
BUME, Desta DoroAddress:
Indianapolis, Indiana 46206-6288, US
Name:
CONDROSKI, Kevin RonaldAddress:
Indianapolis, Indiana 46206-6288, US
Name:
DILGER, Andrew KarlAddress:
Indianapolis, Indiana 46206-6288, US
Name:
HAZLITT, Robert AlanAddress:
Indianapolis, Indiana 46206-6288, US
Name:
KERCHER, Timothy ScottAddress:
Indianapolis, Indiana 46206-6288, US
Name:
METCALF, Andrew TerranceAddress:
Indianapolis, Indiana 46206-6288, US
Name:
URKALAN, Kaveri BalanAddress:
Indianapolis, Indiana 46206-6288, US
Name:
WALLS, Shane MichaelAddress:
Indianapolis, Indiana 46206-6288, US
Agent
Name:
Árnason Faktor ehf.Address:
Guðríðarstíg 2-4, 113, Reykjavík,
Priority
Number:
202163156527 PDate:
4.3.2021Country:
US
Classification
Categories:
A61P 35/00, C07D 471/04
Annual fees
Number
Paid
Expires
Payer
Number: 5
Paid: 5.3.2026
Expires: 2.3.2027
Payer: Árnason Faktor ehf.